Wanzhou Wu

Wanzhou Wu

Auto-generated profile, based on publicly available information

Wanzhou Wu

Coronary Circulation Center, Xiangya Hospital, Central South University, Changsha, China.

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2024 in The FASEB Journal
Verified
Journal Article
Closed access
XWXuan Wang
Xuan Wang
XLXiangbin Liu
Xiangbin Liu
WWWanzhou Wu
Wanzhou Wu
LLLongshen Liao
Longshen Liao
MZMing Zhou
Ming Zhou
MZMin Zhao
Min Zhao

2 October 2025 in Aging Cell
Verified
Journal Article
Open access
YWYue Wang
Yue Wang
JCJing Chen
Jing Chen
XWXuan Wang
Xuan Wang
JLJin Li
Jin Li
SYShujun Yang
Shujun Yang
YBYongping Bai
Yongping Bai
Blood vessels exhibit a pronounced vulnerability to aging and are often at the forefront of systemic aging processes. Vascular endothelial cells, which line blood vessels and directly contact blood flow, are susceptible to damage and play a key role in vascular aging; however, the underlying mechanisms of their aging remain unclear. Here, we identify TRPM7 as a key molecule in vascular endothelial aging. Endothelial deletion of TRPM7 significantly accelerates premature vascular aging in mice. Mechanistically, TRPM7 deficiency reduces lactate production and inhibits the lactylation writer protein p300, leading to decreased histone H3K18 lactylation. This induces a gene expression profile reprogramming, increasing the expression of the senescence gene p21 and decreasing the expression of angiogenesis genes. Inhibiting p21 or supplementing lactate reversed premature vascular endothelial aging caused by TRPM7 deficiency. This study reveals the critical role of the TRPM7‐H3K18la axis in vascular aging, offering potential therapeutic targets for vascular anti‐aging interventions.

28 May 2026 in Communications Biology
Verified
Journal Article
Open access
JCJing Chen
Jing Chen
YWYue Wang
Yue Wang
XWXuan Wang
Xuan Wang
JLJin Li
Jin Li
YLYu Liu
Yu Liu
YBYongping Bai
Yongping Bai
Peripheral arterial disease (PAD) is characterized by impaired angiogenesis, yet the molecular mechanisms linking metabolic dysregulation to epigenetic reprogramming in endothelial cells (ECs) remain poorly understood. Here, we identify hexokinase 2 (HK2) as a critical regulator of angiogenesis through histone lactylation in PAD. In clinical specimens and murine hindlimb ischemia (HLI) models, HK2 expression was significantly downregulated. Functional assays in hypoxia-serum starved (HSS) human umbilical vein ECs (HUVECs) demonstrated that HK2 overexpression rescued angiogenesis by enhancing proliferation, migration, tube formation, and pro-angiogenic protein expression (VEGFA), while HK2 knockdown suppressed these phenotypes. Mechanistically, HK2 deficiency selectively reduced histone H3 lysine 18 lactylation (H3K18la) among eight tested histone lactylation sites, and HK2 restoration under HSS restored H3K18la level. Exogenous lactate reversed angiogenic defects in HK2-knockdown HUVECs by elevating H3K18la, which directly activated VEGFA transcription, as shown by Chromatin Immunoprecipitation coupled with quantitative Polymerase Chain Reaction (ChIP-qPCR). Furthermore, Sirtuin 2 (SIRT2), as a de-lactylase, inhibition in HK2-knockdown HUVECs restored H3K18la, angiogenesis, and pro-angiogenic protein expression. In HLI mice, SIRT2 inhibitor treatment improved blood flow recovery, increased EC density, and upregulated H3K18la. Our findings establish HK2 as a metabolic-epigenetic nexus driving angiogenesis via lactate-dependent H3K18la modification and propose SIRT2 inhibition as a novel therapeutic strategy to bypass HK2 deficiency in PAD.